Development of novel anti-cancer immune therapies targeting CD147 antigen

• Project/Area Number: 15K10590
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Okayama University
• Principal Investigator: Kobayashi Yasuyuki 岡山大学, 大学病院, 講師 (50366027)
• Co-Investigator(Kenkyū-buntansha): 黄 鵬 岡山大学, 医歯薬学総合研究科, 助教 (00610841) ; 渡部 昌実 岡山大学, 大学病院, 教授 (70444677) ; 植木 英雄 岡山大学, 医学部, 技術専門職員 (90537218)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000); Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
• Keywords: 癌治療 / ＣＤ147 / 腫瘍学 / CD147 / 液性免疫 / Emmprin / 抗体

Outline of Final Research Achievements

In this study, we validated and confirmed the anti-cancer immune activity of the fusion proteins consisted of CD147 antigen and cytokines, in in vivo experimental models. We also disclosed the inhibitory function of REIC/Dkk-3 protein overexpressed by Ad-REIC agents, in the endogenous CD147 expression in bladder and prostate cancer cells. We believe that the CD147 antigen could be a promising target for anti-cancer therapy. We are going to conduct the further study to develop novel anti-cancer immune therapies targeting CD147 antigen.

Research Products

• [Journal Article] Overexpression of REIC/Dkk-3 suppresses the expression of CD147 and inhibits the proliferation of human bladder cancer cells.Oncol Lett. (2017)
  • Author(s): Horikawa Y, Watanabe M, Sadahira T, Ariyoshi Y, Kobayashi Y, Araki M, Wada K, Ochiai K, Li SA, Nasu Y.
  • Journal Title: Oncol Lett Volume: 14 Issue: 3 Pages: 3223-3228
  • DOI: 10.3892/ol.2017.6548
  • Peer Reviewed / Open Access